187
Participants
Start Date
April 6, 2022
Primary Completion Date
April 6, 2024
Study Completion Date
April 6, 2024
Semaglutide
Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Centro de Investigacion Clinica Endocrinologica de Jalisco, Guadalajara
CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco SC, Guadalajara
Lead Sponsor
Novo Nordisk A/S
INDUSTRY